Back to Trials
NCT06153667Recruiting

Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)

Merit Medical Systems, Inc.

Start Date

8/22/2024

Completion Date

12/1/2026

Summary

This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Adult women ≥ 18 years old at the time of enrollment. * Subject has symptomatic uterine fibroid(s), suitable to embolization. * Subject provides written informed consent. Exclusion Criteria: * Subject is pregnant. * Subject has suspected pelvic inflammatory disease or any other pelvic infection. * Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).

Interventions

DEVICE

Bearing nsPVA

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Uterine Fibroid

Locations

Astra Vascular/Astra Vein Treatment Center

Brooklyn, New York 11234

United States

The Wesley Hospital

Brisbane,

Australia

Alfred Health

Sydney,

Australia

Royal Gwent Hospital (Aneurin Bevan UHB)

Newport,

United Kingdom